SUBJECT INDEX
A beta fiber, 198
A delta fiber, 198
Abdominal radiation, for extramedullary hematopoiesis in myelofibrosis
with myeloid metaplasia, 408-410
Aberrant crypt foci, 25
as potential surrogate biomarker, 30-31
Aberrant DNA methylation, in cancer, 521
causes of
accelerating factors, 525-526
gene expression factor, 526
seed and spread model, 525
selective advantage, 526-527
in cutaneous malignancies
basal cell carcinoma, 480-481
lymphoma, 483-484
melanoma, 481-483
relationship with exposure to ultraviolet radiation, 484
squamous cell carcinoma, 480-481
Acetaminophen, 183-184
Acupuncture, 226
Acute myelogenous leukemia, clinical development of decitabine for
combination therapy, 469
monotherapy, 468-469
Adenocarcinoma, lung, uracil tegafur adjuvant chemotherapy, 281
Adenomatous polyps, colorectal cancer risk and, 4-5
Adenoviral vectors, for cancer gene therapy, 573-575
adverse outcomes, 580
clinical applications, 576
gene replacement therapy, 578-579
immunotherapy and, 576-578
oncolytic virotherapy, 579-580
suicide gene therapy, 578
targeting of
transcriptional, 575-576
transductional, 575
Affinitak, in non-small cell lung cancer, 320
Age, effects on chemotherapy of non-small cell lung cancer, 308-310
Algomed pump, 195
Allogeneic hemopoietic stem cell transplantation, for myelofibrosis with
myeloid metaplasia, 414-419
ALVAC, 80
American Cancer Society, 216
Amsterdam criteria, for hereditary nonpolyposis colon cancer, 16
Analgesic
for cancer pain relief, 181-184
co-analgesic, 188
dosing of, 183-184
opioid, sequential trials of, 188
Androgens, for anemia in myelofibrosis with myeloid metaplasia, 423
Anemia, in myelofibrosis with myeloid metaplasia, androgens for, 423
Angiogenesis, 61-62
in myelofibrosis with myeloid metaplasia, 385-386
pro, factors for, 62
Angiogenesis inhibitors
in clinical development, 66
factors for, 62
in non-small cell lung cancer, 320-323
Angiogenesis inhibitors (Continued )
trials of, in colorectal cancer, 63
Angiogenic myeloid metaplasia, see Myelofibrosis with myeloid metaplasia
Angiozyme, in colorectal cancer, 65, 66
Anorexia, 202-204
pharmacologic agents for, 201
Antiangiogenic agents, for myelofibrosis with myeloid metaplasia, 424-426
Anticonvulsant, as co-analgesic, 189-190
Anti-EGFR monoclonal antibody therapy
in malignant pleural mesothelioma, 341-343
in non-small cell lung cancer, 317-318
Antigen
processing of, 77
types of, in colorectal cancer, 78
Anti-idiotypic vaccine, trial of, 79
Antineoplastic activity, of decitabine in animal models, 445-446
Antisense oligonucleotides, for oncogene inactivation
Bcl-2 inhibition by, 568-569
cellular internalization, 564-565
chemically synthesized, properties of, 564
clinical utility of phosphodiester oligonucleotides, 563-564
for multidrug resistant cancer, 584-585, 587
phosphorothioate oligonucleotides
efficacy of, and RNAse H, 566
general properties, 565
nonspecific effects, 565-566
pharmacokinetics, 566-569
second-generation oligonucleotides, pharmacokinetics, 568
Anti-VEGFR monoclonal antibody therapy, in non-small cell lung cancer, 320
Anxiety, treatment of, 212-214
APC gene, 15
in colorectal screening, 9
Apoptosis
activation by decitabine in epigenetic cancer therapy, 466
and proliferation, in myelofibrosis with myeloid metaplasia, 383-385
Argon plasma coagulation, 175
Aspirin
chemoprevention trial and, 26
colorectal cancer and, 25-28
Astler-Coller classification, modified, in colorectal cancer, 96
Atypical capsular melanocytes, 596-597
Autofluorescence bronchoscopy, in non-small cell lung cancer screening, 254
Autologous hemopoietic stem cell transplantation, for myelofibrosis with
myeloid metaplasia, 419-420
Avastin, in malignant pleural mesothelioma, 343-344
Avipox, 80
5-Aza-2Ј-deoxycytidine, see Decitabine
5-AZA-CdR, see Decitabine
Azacitidine, in epigenetic cancer therapy
combinations with histone deacetylase inhibitors, 461
dose-schedule optimization of, 459-460
for myeloid neoplasms, 511-512
restoring or enhancing sensitivity to other therapy, 460-461
5-AZA-CR, see Azacitidine
5-Azacytidine, see Azacitidine
Azanucleosides, low-dose, in epigenetic therapy of myeloid neoplasms, 511-512
Azoxymethane, 53
599